Furthermore, this SRS was a widely-used, useful and effective tool to confirm newly developed post-marketing ADRs.3 Analysis of data collected by SRS could provide information about newly detected ADR that was not shown in phase 2 or 3 clinical trial and risk factors for occurrence of serious ADRs.4